Effects of Yangxue Qingnao Granules on chronic cerebral circulation insufficiency: a randomized, double‐blind, double‐dummy, controlled multicentre trial

Abstract

Background: There is a great deal of interest in traditional Chinese medicine as a treatment for chronic cerebral circulation insufficiency (CCCI). In the present study, we evaluated the efficacy and safety of Yangxue Qingnao Granules (YXQNG) as a monotherapy in patients with CCCI. Methods: From July 2007 to May 2010, 273 patients with CCCI at nine centres in China were randomly assigned to receive either YXQNG with nimodipine placebo (n = 140, 12 g/day) or nimodipine with YXQNG placebo (n = 133, 30 mg/day) for 8 weeks. The primary end points after 8 weeks of treatment were changes from baseline in severity of headache, heavyheaded feeling, dizziness and sleep disorder. Results: The mean baseline levels of headache, heavy-headed feeling, dizziness and sleep disorder were comparable between the two groups. Both therapies significantly improved these symptoms after 8 weeks of treatment (P < 0.001). Compared with nimodipine therapy, YXQNG resulted in similar reductions in these symptoms. No adverse effects were observed in the YXQNG group.Conclusions: These data demonstrate that YXQNG as a monotherapy were as effective as nimodipine monotherapy in improving the symptoms of CCCI. It is well-tolerated and may have an important place in the management of this condition. Whether a combination of these two medicines will increase therapeutic efficacy deserves further clinical investigation.

YXQN Reduces Alzheimer’s Disease-Like Pathology and Cognitive Decline in APPswePS1dE9 Transgenic Mice

“…As YXQN formulated on the theoretical and clinical foundations of traditional Chinese medicine, it is effective toward multiple targets, especially, against the cognitive impairment caused by various cerebral vessel-related lesions. Data from 273 patients with chronic cerebral vascular insufficiency (CCI) at 9 hospitals in China demonstrated that, after 8 weeks of treatment, YXQN was as effective as nimodipine in improving the symptoms of CCI, including baseline in severity of headache, heavy-headed feeling, dizziness and sleep disorder (Wu et al, 2013); likewise, research in 83 patients showed that 12-week clinical YXQN treatment could effectively improve the CCI symptoms by reducing the vertigo score, and increasing middle cerebral artery mean velocity and vertebral artery mean velocity (Gu et al, 2005). Further, animal experiments also provided another line of evidence that YXQN increased CBF and attenuated cerebral microcirculatory disturbance in the ischemia-reperfusion injury, and therefore elevated model group rats’ memory performance (Gu et al, 2005; Xu et al, 2009; Xiong et al, 2011).…”

Comparing Cerebralcare Granule and aspirin for neurological dysfunction in acute stroke in real‐life practice

“…demonstrated that cognitive impairment induced by chronic cerebral hypoperfusion could be ameliorated by CG treatment . In a randomized, controlled trial, CG was shown to alleviate headache, heavy‐headed feeling, and dizziness in patients with chronic cerebral circulation insufficiency possibly as a result of increased cerebral blood circulation …”

Advances in chronic cerebral circulation insufficiency

“…Patients with CCCI usually complained of motor or sensory dysfunctions, cognitive decline, and mental or emotional abnormalities. Details are listed in Table A …”